TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15885696

Group type: EXPERIMENTAL
Intervention: 500 mg mebendazole (MBZ)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Thiabendazole (TBZ)
Number of subjects: 470
Study: 12438289

Group type: EXPERIMENTAL
Intervention: Internal mammary artery (IMA) grafts in patients with TDM
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Internal mammary artery (IMA) grafts in patients without TDM
Number of subjects: 1526

Group type: EXPERIMENTAL
Intervention: Vein grafts in patients with TDM
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Vein grafts in patients without TDM
Number of subjects: 1526
Study: 11535474

Group type: EXPERIMENTAL
Intervention: Intrastromal Corneal Ring Segments (ICRS)
Number of subjects: 452
Study: 9430799

Group type: EXPERIMENTAL
Intervention: High carbohydrate meal (HC)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High fat meal (HF)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 9
Study: 8213600

Group type: EXPERIMENTAL
Intervention: Intranasal propranolol spray (5 mg/puff)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3619432

Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 200 mg ciprofloxacin intravenously
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin orally
Number of subjects: 8
Study: 30558006

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (HR) group, infused at a rate of 0.25 μg/kg/min, adjusted by 0.05 μg/kg/min as needed.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-dose remifentanil (LR) group, infused at a rate of 0.05 μg/kg/min.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (HR) group.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-dose remifentanil (LR) group.
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both groups (HR and LR).
Number of subjects: 92
Study: 27421815

Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle aspiration (EUS-FNA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: EUS-guided fine needle biopsy (EUS-FNB)
Number of subjects: 22
Study: 25042870

Group type: EXPERIMENTAL
Intervention: 1mg oral dose of risperidone
Number of subjects: 70
Study: 22180560

Group type: EXPERIMENTAL
Intervention: Lamivudine dosing according to WHO weight band
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine dosing according to FDA label
Number of subjects: 0
Study: 20600017

Group type: COMPARATOR
Intervention: pegylated interferon‐alfa‐2a (Peg‐IFNalfa‐2a) 180 µg/wk
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: albinterferon alfa‐2b (albIFN) 900 µg every 2 weeks
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: albinterferon alfa‐2b (albIFN) 1200 µg every 2 weeks
Number of subjects: 933
Study: 18235117

Group type: EXPERIMENTAL
Intervention: Epoetin beta 30,000 U subcutaneously once weekly for 24 weeks
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 463
Study: 16192550

Group type: EXPERIMENTAL
Intervention: Murphy-tipped ETT without thermosoftening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magill-tipped ETT without thermosoftening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Murphy-tipped ETT with thermosoftening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magill-tipped ETT with thermosoftening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thermosoftening (applied to both ETT types)
Number of subjects: 100
Study: 14623212

Group type: EXPERIMENTAL
Intervention: Instruction that simultaneously challenged children's beliefs concerning why the earth appears flat and the role of gravity
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Instruction that repeatedly challenged only one of these beliefs
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 132
Study: 10851413

Group type: EXPERIMENTAL
Intervention: Cemented acetabular component
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Non-cemented acetabular component
Number of subjects: 16
Study: 8927736

Group type: EXPERIMENTAL
Intervention: Acute hepatitis A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acute hepatitis B
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acute hepatitis C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 2055140

Group type: EXPERIMENTAL
Intervention: 4-day schedule of preoperative pelvic radiotherapy followed by immediate surgery
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group (unirradiated patients)
Number of subjects: 284
Study: 31513163

Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation therapy during standard drug therapy (study group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard drug therapy (control group)
Number of subjects: 68
Study: 28292320

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg three times a day
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 26721135

Group type: EXPERIMENTAL
Intervention: Warm needling combined with element calcium (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (caltrate-D tablet, 600 mg per day, once a day before sleep for one year)
Number of subjects: 85
Study: 23797429

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR) cycle including interval endurance training on a cycle ergometer (3 times a week) and general fitness exercises and resistance training (2 times a week) for 6 months.
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no CR).
Number of subjects: 138
Study: 22099791

Group type: EXPERIMENTAL
Intervention: Everolimus with CsA elimination
Number of subjects: 170

Group type: COMPARATOR
Intervention: CsA minimization
Number of subjects: 170
Study: 19154474

Group type: EXPERIMENTAL
Intervention: Extracorporeal electromagnetic stimulation (ES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham electromagnetic stimulation
Number of subjects: 70
Study: 17923654

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 15182245

Group type: EXPERIMENTAL
Intervention: Enacted information recall
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-enacted information recall
Number of subjects: 0
Study: 11981075

Group type: EXPERIMENTAL
Intervention: i.v. calcium folinate (50 mg/week)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: oral calcium folinate (50 mg/week)
Number of subjects: 60

Group type: COMPARATOR
Intervention: oral folic acid (45 mg/week)
Number of subjects: 60
Study: 9615260

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg daily for 12 months (group A)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No treatment (group B)
Number of subjects: 66
Study: 7544827

Group type: EXPERIMENTAL
Intervention: recombinant erythropoietin (r‐HuEpo)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 2696075

Group type: EXPERIMENTAL
Intervention: Active Anterior Rhinomanometry (A.A.R.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Passive Anterior Rhinomanometry (P.A.R.)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Three methods of rhinomanometry
Number of subjects: 11
Study: 383103

Group type: EXPERIMENTAL
Intervention: EMD 21657 (3X300 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3X1 dragée)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMD 21657
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31487383

Group type: EXPERIMENTAL
Intervention: Rituximab plus prednisone (0.5 or 1.0 mg/kg/day, tapered over 3 or 6 months)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Prednisone alone (1.0 or 1.5 mg/kg/day, tapered over 12 or 18 months)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Rituximab plus prednisone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 74
Study: 31644931

Group type: EXPERIMENTAL
Intervention: State high AMPA (approach-motivated positive affect)
Number of subjects: 165

Group type: COMPARATOR
Intervention: State low AMPA
Number of subjects: 165

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: State high AMPA
Number of subjects: 165
Study: 28798049

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1305
Study: 26016150

Group type: EXPERIMENTAL
Intervention: Palliative external beam radiotherapy with hypofractionation regimes (3 fractions of 6.5 Gy for a total dose of 19.5 Gy, 4 fractions of 6.5 Gy for a total dose of 26 Gy) and standard treatment schedule (total dose of 26 Gy)
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Palliative external beam radiotherapy
Number of subjects: 427
Study: 23720502

Group type: EXPERIMENTAL
Intervention: High-amplitude occipital nerve stimulation (ONS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-amplitude occipital nerve stimulation (ONS)
Number of subjects: 0
Study: 21846380

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Rocuronium (0.6 mg/kg)
Number of subjects: 401
Study: 19024003

Group type: EXPERIMENTAL
Intervention: Artrofoon
Number of subjects: 0
Study: 16753121

Group type: EXPERIMENTAL
Intervention: Polydioxanone sutures
Number of subjects: 770

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 770
Study: 15178171

Group type: EXPERIMENTAL
Intervention: Word naming task with Italian three-syllable words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lexical-semantic impairment
Number of subjects: 0
Study: 11127100

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel (5 g twice daily for five days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral metronidazole (500 mg twice daily for seven days)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.75% metronidazole vaginal gel
Number of subjects: 90
Study: 9324103

Group type: EXPERIMENTAL
Intervention: Alpha1‐adrenoreceptor blocker (bunazosin)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Beta1‐adrenoreceptor blocker (metoprolol)
Number of subjects: 43
Study: 8404944

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 80

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 80
Study: 3095093

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 31902327

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study: 28255654

Group type: EXPERIMENTAL
Intervention: Yogurt drink with oligofructose (20% reduced sugars)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fruit jelly with inulin (30% less sugars)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both interventions (yogurt with oligofructose and fruit jelly with inulin)
Number of subjects: 42
Study: 27048670

Group type: EXPERIMENTAL
Intervention: Vitamin C/E complex supplementation (100 IU of vitamin E + 500 mg of vitamin C) twice per day during radiotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vitamin C/E complex supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vitamin C/E complex supplementation and Placebo
Number of subjects: 45
Study: 26298797

Group type: EXPERIMENTAL
Intervention: Polyphenon E (800mg EGCG daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 24096631

Group type: EXPERIMENTAL
Intervention: Early initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (2 weeks)
Number of subjects: 597

Group type: COMPARATOR
Intervention: Late initiation of antiretroviral therapy (ART) after tuberculosis treatment onset (8 weeks)
Number of subjects: 597
Study: 20679159

Group type: EXPERIMENTAL
Intervention: Pedialyte
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pediatric Electrolyte
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Enfalyte
Number of subjects: 66

Group type: COMPARATOR
Intervention: Enfalyte vs Pediatric Electrolyte
Number of subjects: 66

Group type: COMPARATOR
Intervention: Enfalyte vs Pedialyte
Number of subjects: 66

Group type: COMPARATOR
Intervention: Best-tasting solution
Number of subjects: 66
Study: 18782781

Group type: EXPERIMENTAL
Intervention: Daptomycin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Vancomycin plus gentamicin
Number of subjects: 88
Study: 17357307

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis solutions with low content of glucose degradation products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amino acid‐based, icodextrin‐based or glycerol‐based dialysis solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate or pyruvate as a buffer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraperitoneal drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Techniques to decrease infection rate
Number of subjects: 0
Study: 12661776

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) for 2 years
Number of subjects: 36
Study: 10719007

Group type: EXPERIMENTAL
Intervention: Grepafloxacin 400 mg od for 10 days
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg bd for 10 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Grepafloxacin
Number of subjects: 25
Study: 8957979

Group type: EXPERIMENTAL
Intervention: Ketamine (racemic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ketamine (S+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1416684

Group type: EXPERIMENTAL
Intervention: Scoring system for diagnosis and management of acute appendicitis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard appendicectomy procedure
Number of subjects: 58
Study: 3776447

Group type: EXPERIMENTAL
Intervention: Enflurane 5 vol% in 70% nitrous oxide in oxygen via a face mask
Number of subjects: 83

Group type: COMPARATOR
Intervention: Thiopental 5 mg/kg followed by suxamethonium 1.5 mg/kg i.v.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Enflurane with suxamethonium 2 mg/kg
Number of subjects: 83
Study: 30929823

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg/day until disease progression or unacceptable toxicity
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg/day
Number of subjects: 27
Study: 27841945

Group type: EXPERIMENTAL
Intervention: Greater expression of intestinal cholesterol metabolism genes (NPC1L1, ABC‐G5, ABC‐G8, ABC‐A1, MTTP, SREBP‐2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Greater expression of NPC1L1, ABC‐G8, and SREBP‐2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Greater expression of MTTP, ABC‐A1, and SREBP‐2
Number of subjects: 100
Study: 26002728

Group type: EXPERIMENTAL
Intervention: 500 mg resveratrol for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 50
Study: 23246855

Group type: EXPERIMENTAL
Intervention: 20mg d-amphetamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 12
Study: 21274547

Group type: EXPERIMENTAL
Intervention: Oral intake of a venotonic drug (micronized purified flavonoid fraction, Daflon 1,000 mg × 3) for 20 days
Number of subjects: 81

Group type: COMPARATOR
Intervention: Standard conservative treatment alone
Number of subjects: 81
Study: 19846544

Group type: EXPERIMENTAL
Intervention: Dietary intervention plus n-3 fatty acid supplementation (6 g/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dietary intervention plus n-3 fatty acid supplementation
Number of subjects: 54
Study: 16895071

Group type: EXPERIMENTAL
Intervention: Risedronate, 2.5 mg/day, daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo, daily
Number of subjects: 23
Study: 14711555

Group type: EXPERIMENTAL
Intervention: PCOS patients with AA excess
Number of subjects: 30

Group type: COMPARATOR
Intervention: PCOS patients without AA excess
Number of subjects: 30
Study: 11854119

Group type: EXPERIMENTAL
Intervention: Weight loss program (diet, exercise, behavioral counseling)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 56
Study: 9602595

Group type: COMPARATOR
Intervention: 0.9% sodium chloride (saline) 50 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine solution with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 ml of 2% lidocaine with epinephrine 1:200,000 diluted with saline to a final volume of 50 ml
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 8022633

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal cord injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NASCIS dose of methylprednisolone
Number of subjects: 0
Study: 3046231

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg, 4 times a day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Aspirin (650 mg, 4 times a day)
Number of subjects: 52
Study: 31121022

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study: 28914681

Group type: EXPERIMENTAL
Intervention: Collagen/Oxidized Regenerated Cellulose/Silver with Standard of Care (SOC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard of Care (SOC) alone
Number of subjects: 49
Study: 25567818

Group type: EXPERIMENTAL
Intervention: BREATHE OUT intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study: 23704713

Group type: EXPERIMENTAL
Intervention: Vildagliptin (DPP4 inhibitor) during OGTT
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no DPP4i) during OGTT
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Isoglycaemic i.v. glucose infusion (IIGI)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: DPP4i in controls
Number of subjects: 26
Study: 21292809

Group type: EXPERIMENTAL
Intervention: Weight loss + physical activity (WL + PA)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Physical activity only (PA)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Successful aging (SA) health education program
Number of subjects: 288
Study: 19138452

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy in addition to standard medical therapy (prednisolone starting at 1 mg/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard medical therapy (prednisolone starting at 1 mg/kg)
Number of subjects: 57
Study: 16523808

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 60 Gy in 30 fractions
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose of 74 Gy at 2 Gy/fraction
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Radiotherapy dose escalation
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Surviving fraction of tumour cells after a radiation dose of 2 Gy (SF2)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Delay to start radiotherapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 154
Study: 14718694

Group type: EXPERIMENTAL
Intervention: Botulinum toxin B (1,000 units into each parotid gland and 250 units into each submandibular gland)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11522564

Group type: EXPERIMENTAL
Intervention: 5 mg elemental Zinc daily for 5 months
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study: 9266735

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (average of 25 days)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 66
Study: 7507765

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (30 mg, p.o.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 2906887

Group type: EXPERIMENTAL
Intervention: 60 mg terfenadine-120 mg pseudoephedrine hydrochloride combination
Number of subjects: 315

Group type: COMPARATOR
Intervention: 120 mg pseudoephedrine hydrochloride (extended release)
Number of subjects: 315
Study: 29632101

Group type: EXPERIMENTAL
Intervention: Multidomain training (n=55)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Usual care (n=58)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 113
Study: 28668627

Group type: EXPERIMENTAL
Intervention: 3.0g vigabatrin solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6.0g vigabatrin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: 400 mg moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo vigabatrin solution
Number of subjects: 0
Study: 25904205

Group type: EXPERIMENTAL
Intervention: PPNa-DBS combined with levodopa treatment
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PPNa-DBS
Number of subjects: 6

Group type: COMPARATOR
Intervention: Without PPNa-DBS
Number of subjects: 6
Study: 23556334

Group type: EXPERIMENTAL
Intervention: Posaconazole suspension administered orally in the fasted state
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posaconazole suspension administered orally with a high-fat meal
Number of subjects: 0
Study: 20512484

Group type: EXPERIMENTAL
Intervention: Intervention group instructed to maintain gaze on each target until heel contact
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 16